Associated Genetic Biomarkers
NCI Definition: Proliferation of myeloid cells originating from a primitive stem cell. 
Myeloid neoplasms most frequently harbor alterations in TET2, ASXL1, DNMT3A, TP53, and JAK2 .
JAK2 Mutation, JAK2 V617F, JAK2 Exon 14 Mutation, DNMT3A Mutation, and TP53 Mutation are the most common alterations in myeloid neoplasm .
There are 8 clinical trials for myeloid neoplasm, of which 8 are open and 0 are completed or closed. Of the trials that contain myeloid neoplasm as an inclusion criterion, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open).
FGFR1, CBL, and CSF3R are the most frequent gene inclusion criteria for myeloid neoplasm clinical trials .
Allogeneic hematopoietic stem cell transplantation, anti-cd123 chimeric antigen receptor t-cells, and cladribine are the most common interventions in myeloid neoplasm clinical trials.
Significant Genes in Myeloid Neoplasm
PDGFRA is altered in 0.53% of myeloid neoplasm patients .
PDGFRA is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
PTEN is altered in 0.31% of myeloid neoplasm patients .
PTEN is an inclusion eligibility criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.